[Current aspects of prostate cancer screening]

Screening programs for prostate cancer based on the determination of serum prostate specific antigen has led to overdiagnosis, and consequently overtreatment. A percentage of men diagnosed with prostate cancer have a tumour that will not progress, or do so slowly (overdiagnosis or pseudo-disease). This overdiagnosis rate ranges from 17-50%. Mass screening is defined as the systematic examination of asymptomatic men. Early detection or opportunistic screening involves the pursuit of individual cases being initiated by the doctor or the patient. In the case of a patient who requests a prostate specific antigen from their general practitioner, a number of issues on overdiagnosis, over-treatment and possible damage from the biopsy, should be explained to him. With data from randomised studies on prostate specific antigen and prostate cancer screening, population screening is not recommended by any urological society.

Semergen / Sociedad Espanola de Medicina Rural y Generalista. 2016 Aug 22 [Epub ahead of print]

A Jalón Monzón, S Escaf Barmadah, L M Viña Alonso, M Jalón Monzón

Servicio de Urología, Hospital Universitario Central de Asturias (HUCA), Oviedo, Asturias, España. Electronic address: ., Servicio de Urología, Hospital Universitario Central de Asturias (HUCA), Oviedo, Asturias, España., Centro de Salud El Parque-Somió, Gijón, Asturias, España., Centro de Salud de Contrueces, Gijón, Asturias, España.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe